Shuli Li
Papers
2
Total Citations
110
H-Index
2
About
Dr. Shuli Li is a leading clinical researcher in head and neck oncology, with a primary focus on treatment de-intensification for HPV-related oropharyngeal cancer. Her most impactful work centers on the landmark ECOG-ACRIN E3311 trial, which investigates whether reducing postoperative radiation doses can maintain excellent cure rates while minimizing long-term toxicity for patients with p16+ oropharynx cancer. As a key contributor to this practice-changing study, Dr. Li helped demonstrate the feasibility of lowering adjuvant IMRT from 60 Gy to 50 Gy in intermediate-risk patients, with the trial’s primary endpoint of 2-year progression-free survival showing promising results. Her work has garnered over 100 citations for the E3311 trial alone, reflecting its significant influence on clinical guidelines. Beyond the trial’s outcomes, Dr. Li also pioneered a novel surgeon credentialing and quality assurance process for transoral robotic surgery, ensuring standardized surgical techniques across multiple institutions. This methodological contribution has been essential for maintaining trial integrity and has set a new benchmark for multi-center surgical trials. Dr. Li’s research continues to shape the paradigm of personalized, less toxic treatment for patients with HPV-positive head and neck cancers.
Research Focus
Key Achievements
Top Papers
- 1
- 2